MyCartis

MyCartis NV operated in the clinical and translational research market, focusing on personalized healthcare by developing solutions for biomarker analysis. The company was established in September 2014, resulting from the merger of Ghent-based Pronota, a firm developing biomarker panels, and the Biocartis Evalution Business unit from Lausanne, which was producing a multiplex platform for biomarker evaluation. The goal was to bridge the gap between research and clinical practice. MyCartis secured a significant Series A funding round of $19.6 million on September 5, 2014, with lead investor Valiance Asset Management, alongside other institutional and angel investors. The company was eventually acquired by Agilent Technologies, although specific details of the acquisition are not publicly available.

The core of MyCartis's business was the development and commercialization of its Evalution™ platform, which was based on a proprietary Dynamic Multi-Analyte Technology (DMAT®). This platform was designed for the rapid and sensitive detection of a wide array of biomarkers, including proteins and nucleic acids, from various sample types like blood and cerebrospinal fluid. The technology utilized 40-micron binary-coded silicon microparticles, allowing for the simultaneous analysis of up to 150 analytes in a single, streamlined workflow. This capability was aimed at assisting researchers and clinicians in biomarker verification, validation, and the translation of new findings into clinical applications. The business model involved making this technology available to research and clinical communities and collaborating with partners from industry and academia to develop and commercialize biomarker assays for various diseases, including heart failure, autoimmune diseases, and oncology. The company served clients in the clinical research and pharmaceutical markets.

The Evalution™ platform was the company's flagship product, a multiplex diagnostic system that provided an integrated environment for reaction and detection. Its main benefit was the ability to quantify different types of biomarkers on a single platform, which helps in generating more comprehensive and coherent multiplex data sets. This was intended to support quicker and more accurate treatment decisions by providing detailed individual biomarker profiles. MyCartis positioned its technology against other multiplex technology providers by highlighting the unique combination of speed, sensitivity, and reproducibility offered by the Evalution™ platform. The development of the instrument involved a close partnership with Invetech, which handled the instrument design, prototyping, and testing to tailor the solution for the target markets. Keywords: biomarker analysis, multiplex platform, personalized healthcare, clinical research, diagnostic solutions, Evalution platform, DMAT technology, translational research, protein analysis, nucleic acid detection, multiplex assay, biomarker validation, immunodiagnostics, life sciences, molecular diagnostics, syndromic panels, in-vitro diagnostics, microfluidics, biomedical technology, clinical laboratory techniques